NOVONIX LTD-ADR (NVX)

US67010L1008 - ADR

1.88  +0.08 (+4.44%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NVX. NVX was compared to 126 industry peers in the Electronic Equipment, Instruments & Components industry. NVX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NVX is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

NVX had negative earnings in the past year.
NVX had a negative operating cash flow in the past year.
NVX had negative earnings in each of the past 5 years.
NVX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -19.46%, NVX is not doing good in the industry: 73.55% of the companies in the same industry are doing better.
NVX has a worse Return On Equity (-29.65%) than 73.55% of its industry peers.
Industry RankSector Rank
ROA -19.46%
ROE -29.65%
ROIC N/A
ROA(3y)-14.15%
ROA(5y)-28.77%
ROE(3y)-18.11%
ROE(5y)-50.01%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

NVX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NVX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NVX has more shares outstanding
The debt/assets ratio for NVX is higher compared to a year ago.

2.2 Solvency

NVX has an Altman-Z score of 0.47. This is a bad value and indicates that NVX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.47, NVX is not doing good in the industry: 76.86% of the companies in the same industry are doing better.
NVX has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
NVX's Debt to Equity ratio of 0.44 is on the low side compared to the rest of the industry. NVX is outperformed by 68.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 0.47
ROIC/WACCN/A
WACC10.17%

2.3 Liquidity

NVX has a Current Ratio of 6.15. This indicates that NVX is financially healthy and has no problem in meeting its short term obligations.
NVX has a Current ratio of 6.15. This is amongst the best in the industry. NVX outperforms 87.60% of its industry peers.
NVX has a Quick Ratio of 5.94. This indicates that NVX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NVX (5.94) is better than 89.26% of its industry peers.
Industry RankSector Rank
Current Ratio 6.15
Quick Ratio 5.94

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 39.81% over the past year.
Looking at the last year, NVX shows a very negative growth in Revenue. The Revenue has decreased by -17.47% in the last year.
The Revenue has been growing by 27.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)39.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.75%
Revenue 1Y (TTM)-17.47%
Revenue growth 3Y16.92%
Revenue growth 5Y27.36%
Sales Q2Q%-6.35%

3.2 Future

The Earnings Per Share is expected to decrease by -28.11% on average over the next years. This is quite bad
The Revenue is expected to grow by 67.12% on average over the next years. This is a very strong growth
EPS Next Y-2.11%
EPS Next 2Y-10%
EPS Next 3Y-4.29%
EPS Next 5Y-28.11%
Revenue Next Year40.44%
Revenue Next 2Y167.86%
Revenue Next 3Y179.22%
Revenue Next 5Y67.12%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as NVX's earnings are expected to decrease with -4.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10%
EPS Next 3Y-4.29%

More info and screens

0

5. Dividend

5.1 Amount

NVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVONIX LTD-ADR

NASDAQ:NVX (1/2/2025, 12:50:13 PM)

1.88

+0.08 (+4.44%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)09-25 2024-09-25/amc
Earnings (Next)N/A N/A
Inst Owners7.87%
Inst Owner Change-8.04%
Ins Owners3.95%
Ins Owner ChangeN/A
Market Cap266.93M
Analysts84
Price Target1.91 (1.6%)
Short Float %0.06%
Short Ratio1.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.89%
PT rev (3m)6.99%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)13.06%
EPS NY rev (3m)13.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 34.2
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 1.83
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.05
BVpS1.11
TBVpS1.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.46%
ROE -29.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.15%
ROA(5y)-28.77%
ROE(3y)-18.11%
ROE(5y)-50.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 198.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.15
Quick Ratio 5.94
Altman-Z 0.47
F-Score2
WACC10.17%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.75%
EPS Next Y-2.11%
EPS Next 2Y-10%
EPS Next 3Y-4.29%
EPS Next 5Y-28.11%
Revenue 1Y (TTM)-17.47%
Revenue growth 3Y16.92%
Revenue growth 5Y27.36%
Sales Q2Q%-6.35%
Revenue Next Year40.44%
Revenue Next 2Y167.86%
Revenue Next 3Y179.22%
Revenue Next 5Y67.12%
EBIT growth 1Y23.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.02%
EBIT Next 3Y16.12%
EBIT Next 5Y12.19%
FCF growth 1Y64.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.05%
OCF growth 3YN/A
OCF growth 5YN/A